Phaseline

Companies › Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KPL-387–Phase 2Pericarditis; Recurrent PericarditisDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07010159KPL-387Phase 2PericarditisCardiovascularDec 2027
NCT07288216KPL-387Phase 2Recurrent PericarditisCardiovascularDec 2027

From the company's SEC filings

Cash and short-term investments of $569m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Thryv Therapeutics Theravance Biopharma Boston Scientific Tectonic Therapeutic Tectonic Operating Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.